retatrutide clinical trials review trial results 2024 2025 press release A of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity Lilly's triple agonist, retatrutide, delivered – Retatrutide clinical trial done! Now

Trial protocols for obesity or metabolic disease do not support unsupervised use for appearance, performance, or rapid weight change

Sustainable brands will attract sustainability-conscious consumers, promoting brand loyalty and leading to market growth

All medical conditions require evaluation and treatment from qualified healthcare providers using evidence-based approaches appropriate for the specific condition

Leave us your details and our clinic will get back to you shortly

Back Phelan, M (30 May 2024) 'Winning researchers unlocked GLP-1 drugs for obesity', Science , 384/6699

Beena PS, Basheer SM, Bhat SG, Chandrasekaran M